Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

NCT03789162 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).

Conditions Studied

Study Locations (20)

California

  • Alliance Research Institute — Canoga Park
  • GW Research Inc — Chula Vista
  • Tilda Research — Laguna Hills
  • Clinical Trials Network — San Diego

Illinois

  • Rush University Medical Center — Chicago
  • DM Clinical Research/Southwest Gastroenterology — Oak Lawn
  • Southern Illinois University School of Medicine — Springfield
  • Carle Foundation Hospital dba Carle Cancer Center — Urbana

Louisiana

  • MZS Research, LLC — Metairie
  • Delta Research Partners — Monroe
  • Louisiana Research Center, LLC — Shreveport
  • Clinical Trials of America, LLC — West Monroe

Connecticut

  • Gastroenterology Associates of Fairfield County, P.C. — Fairfield
  • Connecticut Clinical Research Institute — Hartford
  • Yale University — New Haven

Indiana

  • Deaconess Clinic, Inc. — Evansville
  • Digestive Research Alliance of Michiana, LLC — South Bend

Arizona

  • Mayo Clinic - Arizona — Phoenix

Florida

  • Guardian Angel Research Center — Tampa

Maryland

  • Capitol Research — Rockville

Trial Details

FieldValue
Enrollment Target 850 participants
Start Date 2018-12-20
Est. Completion 2025-05-29

Sponsor

Exact Sciences Corporation

42 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03789162

The ClinicalTrials.gov registry entry for NCT03789162 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exact Sciences Corporation, which has 42 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03789162 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Illinois, Louisiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03789162 about?

NCT03789162 is a clinical study titled "Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast". The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).

What is the current status of trial NCT03789162?

This trial is currently completed. The enrollment target is 850 participants. The study started on 2018-12-20. Estimated completion is 2025-05-29.

What conditions does trial NCT03789162 study?

This clinical trial studies the following conditions: Colorectal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT03789162?

This trial is sponsored by Exact Sciences Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03789162 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial